ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

VRX Bausch Health Cos

23.40
0.00 (0.00%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Bausch Health Cos NYSE:VRX NYSE Ordinary Share
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 23.40 0.00 01:00:00

Valeant Will Release First-Quarter 2018 Financial Results On May 8

06/04/2018 1:00pm

PR Newswire (Canada)


Valeant Pharma (NYSE:VRX)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Valeant Pharma Charts.

LAVAL, Quebec, April 6, 2018 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") will release its first-quarter 2018 financial results on Tuesday, May 8, 2018. Valeant will host a conference call and live web cast at 8:00 a.m. EDT to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Valeant web site prior to the start of the call.

 

Conference Call Details


Date:

Tuesday, May 8, 2018

Time:

8:00 a.m. EDT

Webcast:

http://ir.valeant.com/events-and-presentations

Participant Event Dial-in: 

(844) 428-3520 (North America)


(409) 767-8386 (International) 

Participant Passcode:

6185877

Replay Dial-in:

(855) 859-2056 (North America)


(404) 537-3406 (International) 

Replay Passcode:

6185877 (replay available until July 8, 2018)

 

About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.valeant.com.

 

Investor Contact:

Media Contact:

Arthur Shannon

Lainie Keller

arthur.shannon@valeant.com

lainie.keller@valeant.com

(514) 856-3855

(908) 927-0617

Valeant Pharmaceuticals International, Inc. (PRNewsFoto/Valeant Pharmaceuticals International, Inc.) (PRNewsFoto/)

 

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/valeant-will-release-first-quarter-2018-financial-results-on-may-8-300624661.html

SOURCE Valeant Pharmaceuticals International, Inc.

Copyright 2018 Canada NewsWire

1 Year Valeant Pharma Chart

1 Year Valeant Pharma Chart

1 Month Valeant Pharma Chart

1 Month Valeant Pharma Chart

Your Recent History

Delayed Upgrade Clock